Linked Life Data

21713364

Source:http://linkedlifedata.com/resource/pubmed/id/21713364

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2011-8-8
pubmed:abstractText
Intratumoral immune cells and ERCC1 expression are likely to play a role in the response of ovarian carcinoma to chemotherapy, but their impact on therapy outcome is still unclear. Therefore, 41 cases of optimally resected high grade serous ovarian carcinomas were examined retrospectively for stromal and intraepithelial lymphocyte populations and ERCC1 status in relation to response to platinum-based therapy. Based on RECIST criteria, 27 patients were classified as responsive and 14 as therapy resistant, respectively. Using immunohistochemistry for CD3, CD8, CD4, TIA1, MUM1 and FOX P3 on representative tumor sections, we quantitatively evaluated the intratumoral density of lymphocyte subpopulations. In addition, ERCC1 protein and mRNA expression were determined by immunohistochemistry using the Steffensen score and quantitative RT-PCR, respectively. Furthermore, ERCC1 SNP's C8092A and codon 118 were analysed. Response to chemotherapy was significantly associated with higher numbers of stromal CD3+ (mean 21.33 lymphocytes/HPF versus 8.21 lymphocytes/HPF, p?=?0.002) and CD8+ lymphocytes (mean 9.22 lymphocytes/HPF versus 4.57 lymphocytes/HPF, p?=?0.013). Counts of intraepithelial CD3+ and CD8+ lymphocytes, stromal and intraepithelial FOXP3+ and TIA1+ cells, CD4+ lymphocytes, and MUM1+ plasma cells did not reach statistical significance. Neither ERCC1 protein expression (p?=?0.232) nor SNPs codon 118 and C8092A of the ERCC1 gene (p?=?0.269 and p?=?0.543) showed an association with therapy response. The same was true for ERCC1 mRNA levels (p?=?0.896), probably due to intratumoral lymphocyte contamination. In conclusion, the density of CD3+ and CD8+ T-cells in tumor stroma proved to be a significant predictor for response to platinum-based therapy, whereas examination of ERCC1 failed to identify therapy-responsive patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1432-2307
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
459
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
183-91
pubmed:meshHeading
pubmed-meshheading:21713364-Adult, pubmed-meshheading:21713364-Aged, pubmed-meshheading:21713364-Antineoplastic Agents, pubmed-meshheading:21713364-Cystadenocarcinoma, Serous, pubmed-meshheading:21713364-DNA-Binding Proteins, pubmed-meshheading:21713364-Drug Resistance, Neoplasm, pubmed-meshheading:21713364-Endonucleases, pubmed-meshheading:21713364-Female, pubmed-meshheading:21713364-Humans, pubmed-meshheading:21713364-Immunohistochemistry, pubmed-meshheading:21713364-Lymphocytes, Tumor-Infiltrating, pubmed-meshheading:21713364-Middle Aged, pubmed-meshheading:21713364-Ovarian Neoplasms, pubmed-meshheading:21713364-Platinum Compounds, pubmed-meshheading:21713364-Polymorphism, Single Nucleotide, pubmed-meshheading:21713364-RNA, Messenger, pubmed-meshheading:21713364-Retrospective Studies, pubmed-meshheading:21713364-Reverse Transcriptase Polymerase Chain Reaction
pubmed:year
2011
pubmed:articleTitle
Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy.
pubmed:affiliation
Department of Pathology, Krankenhaus Barmherzige Schwestern Linz, Seilerstätte 4, 4020, Linz, Austria. hans-christian.boesmueller@bhs.at
pubmed:publicationType
Journal Article